JP2012523458A - タンパク質ホスファターゼ２ａ活性化剤 - Google Patents
タンパク質ホスファターゼ２ａ活性化剤 Download PDFInfo
- Publication number
- JP2012523458A JP2012523458A JP2012506102A JP2012506102A JP2012523458A JP 2012523458 A JP2012523458 A JP 2012523458A JP 2012506102 A JP2012506102 A JP 2012506102A JP 2012506102 A JP2012506102 A JP 2012506102A JP 2012523458 A JP2012523458 A JP 2012523458A
- Authority
- JP
- Japan
- Prior art keywords
- group
- chroman
- yloxy
- dimethyl
- enyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000006478 Protein Phosphatase 2 Human genes 0.000 title claims abstract description 7
- 108010058956 Protein Phosphatase 2 Proteins 0.000 title claims abstract description 7
- 239000012190 activator Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 89
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 108010080146 androgen receptors Proteins 0.000 claims abstract description 52
- 102000001307 androgen receptors Human genes 0.000 claims abstract description 52
- 230000000694 effects Effects 0.000 claims abstract description 51
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 22
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 230000001419 dependent effect Effects 0.000 claims abstract description 13
- -1 4,8-dimethyl-non-1-enyl group Chemical group 0.000 claims description 80
- 201000011510 cancer Diseases 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 38
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical class OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 abstract description 67
- 238000011282 treatment Methods 0.000 abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 239000000969 carrier Substances 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 6
- 239000007787 solid Substances 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 90
- 101710154778 Thymidylate synthase 1 Proteins 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 239000003814 drug Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000002253 acid Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 102000016914 ras Proteins Human genes 0.000 description 15
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 14
- 210000000064 prostate epithelial cell Anatomy 0.000 description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 10
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 239000013543 active substance Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000003098 androgen Substances 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000012139 lysis buffer Substances 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 101150029129 AR gene Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 108010039627 Aprotinin Proteins 0.000 description 5
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 5
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 5
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 5
- 229960004405 aprotinin Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000030609 dephosphorylation Effects 0.000 description 5
- 238000006209 dephosphorylation reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 5
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 5
- 108010052968 leupeptin Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000037426 transcriptional repression Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 229950009811 ubenimex Drugs 0.000 description 5
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 4
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229940126586 small molecule drug Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- FYAQQULBLMNGAH-UHFFFAOYSA-N hexane-1-sulfonic acid Chemical compound CCCCCCS(O)(=O)=O FYAQQULBLMNGAH-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LMTZFBSTLPANJL-UHFFFAOYSA-N 3-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]propanoic acid Chemical compound OC(=O)CCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 LMTZFBSTLPANJL-UHFFFAOYSA-N 0.000 description 2
- IFSHQJYCJIRVAK-UHFFFAOYSA-N 4-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 IFSHQJYCJIRVAK-UHFFFAOYSA-N 0.000 description 2
- MMIUXSFYSAFLQT-UHFFFAOYSA-N 5-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 MMIUXSFYSAFLQT-UHFFFAOYSA-N 0.000 description 2
- FVTXENMRRGKTJO-UHFFFAOYSA-N 6-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]hexanoic acid Chemical compound OC(=O)CCCCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 FVTXENMRRGKTJO-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 101150033538 Rala gene Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical group C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000003616 phosphatase activity assay Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000001189 phytyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LFZQJVPIEFDJER-UHFFFAOYSA-N (2,5,7,8-tetramethyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxymethylphosphonic acid Chemical compound OP(=O)(O)COC1=C(C)C(C)=C2OC(C=CCCCCCCC)(C)CCC2=C1C LFZQJVPIEFDJER-UHFFFAOYSA-N 0.000 description 1
- BFWPOGLXJJQOQK-UHFFFAOYSA-N (2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxymethanesulfonic acid Chemical compound OS(=O)(=O)COC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C BFWPOGLXJJQOQK-UHFFFAOYSA-N 0.000 description 1
- HGBPXJMMJMOERZ-UHFFFAOYSA-N (2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxymethylphosphonic acid Chemical compound OP(=O)(O)COC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C HGBPXJMMJMOERZ-UHFFFAOYSA-N 0.000 description 1
- SWNNJZLROIRNTO-UHFFFAOYSA-N (2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxymethylphosphonic acid Chemical compound OP(=O)(O)COC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 SWNNJZLROIRNTO-UHFFFAOYSA-N 0.000 description 1
- DANIVBBBJORASH-UHFFFAOYSA-N (2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxymethanesulfonic acid Chemical compound OS(=O)(=O)COC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 DANIVBBBJORASH-UHFFFAOYSA-N 0.000 description 1
- XVSWQLIKLIQTAU-UHFFFAOYSA-N (2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxymethylphosphonic acid Chemical compound OP(=O)(O)COC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 XVSWQLIKLIQTAU-UHFFFAOYSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- JWDWLLONDACDQR-UHFFFAOYSA-N 1-[(2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]butane-1-sulfonic acid Chemical compound CCCC(S(O)(=O)=O)OC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 JWDWLLONDACDQR-UHFFFAOYSA-N 0.000 description 1
- PFFPWYGXMBPYJV-UHFFFAOYSA-N 1-[(2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]hexane-1-sulfonic acid Chemical compound CCCCCC(S(O)(=O)=O)OC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 PFFPWYGXMBPYJV-UHFFFAOYSA-N 0.000 description 1
- INXFQDJHPDRJIP-UHFFFAOYSA-N 1-[(2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]pentane-1-sulfonic acid Chemical compound CCCCC(S(O)(=O)=O)OC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 INXFQDJHPDRJIP-UHFFFAOYSA-N 0.000 description 1
- NORQBERVSDJNHY-UHFFFAOYSA-N 1-[(2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]propane-1-sulfonic acid Chemical compound CCC(S(O)(=O)=O)OC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 NORQBERVSDJNHY-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- JVQMHYXRKLCLRA-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]acetic acid Chemical compound OC(=O)COC1=C(C)C(C)=C2OC(C=CCCCCCCC)(C)CCC2=C1C JVQMHYXRKLCLRA-UHFFFAOYSA-N 0.000 description 1
- YRBLXQOIKSDMQN-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]ethanesulfonic acid Chemical compound OS(=O)(=O)CCOC1=C(C)C(C)=C2OC(C=CCCCCCCC)(C)CCC2=C1C YRBLXQOIKSDMQN-UHFFFAOYSA-N 0.000 description 1
- HSRMYCAOOVOIMK-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]ethylphosphonic acid Chemical compound OP(=O)(O)CCOC1=C(C)C(C)=C2OC(C=CCCCCCCC)(C)CCC2=C1C HSRMYCAOOVOIMK-UHFFFAOYSA-N 0.000 description 1
- GJLNFMAKOICDQB-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]pentylphosphonic acid Chemical compound CCCC(CP(O)(O)=O)OC1=C(C)C(C)=C2OC(C=CCCCCCCC)(C)CCC2=C1C GJLNFMAKOICDQB-UHFFFAOYSA-N 0.000 description 1
- GCVOVJSTUDFIGB-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]acetic acid Chemical compound OC(=O)COC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C GCVOVJSTUDFIGB-UHFFFAOYSA-N 0.000 description 1
- RQLBXSUFABQHAD-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]butylphosphonic acid Chemical compound OP(=O)(O)CC(CC)OC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C RQLBXSUFABQHAD-UHFFFAOYSA-N 0.000 description 1
- ORVXDXOJPQNUDU-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]ethanesulfonic acid Chemical compound OS(=O)(=O)CCOC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C ORVXDXOJPQNUDU-UHFFFAOYSA-N 0.000 description 1
- SFLVBAUVOAZMHL-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]ethylphosphonic acid Chemical compound OP(=O)(O)CCOC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C SFLVBAUVOAZMHL-UHFFFAOYSA-N 0.000 description 1
- MXTYBRWNEQDLLT-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]hexylphosphonic acid Chemical compound CCCCC(CP(O)(O)=O)OC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C MXTYBRWNEQDLLT-UHFFFAOYSA-N 0.000 description 1
- MJQLANGNBHGHOC-UHFFFAOYSA-N 2-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]propylphosphonic acid Chemical compound OP(=O)(O)CC(C)OC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C MJQLANGNBHGHOC-UHFFFAOYSA-N 0.000 description 1
- ICNHRKBZMPPHNM-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 ICNHRKBZMPPHNM-UHFFFAOYSA-N 0.000 description 1
- WVTJSFDQIQELKU-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(CC)OC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 WVTJSFDQIQELKU-UHFFFAOYSA-N 0.000 description 1
- YZTRWSNBWQUWTO-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]butylphosphonic acid Chemical compound OP(=O)(O)CC(CC)OC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 YZTRWSNBWQUWTO-UHFFFAOYSA-N 0.000 description 1
- GZQUNOCUCKFBFN-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]ethanesulfonic acid Chemical compound OS(=O)(=O)CCOC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 GZQUNOCUCKFBFN-UHFFFAOYSA-N 0.000 description 1
- IWLZNRXDXMSMDQ-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]ethylphosphonic acid Chemical compound OP(=O)(O)CCOC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 IWLZNRXDXMSMDQ-UHFFFAOYSA-N 0.000 description 1
- QKUXRICZXGXCNJ-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]hexane-1-sulfonic acid Chemical compound CCCCC(CS(O)(=O)=O)OC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 QKUXRICZXGXCNJ-UHFFFAOYSA-N 0.000 description 1
- XTEAXPRBRSLVDI-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]hexylphosphonic acid Chemical compound CCCCC(CP(O)(O)=O)OC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 XTEAXPRBRSLVDI-UHFFFAOYSA-N 0.000 description 1
- GMJMIUFAZNCBNR-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]pentane-1-sulfonic acid Chemical compound CCCC(CS(O)(=O)=O)OC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 GMJMIUFAZNCBNR-UHFFFAOYSA-N 0.000 description 1
- IEKNHJXWBNOCGH-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]propane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(C)OC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 IEKNHJXWBNOCGH-UHFFFAOYSA-N 0.000 description 1
- XOTFLRFOBUSVDA-UHFFFAOYSA-N 2-[(2-methyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]propylphosphonic acid Chemical compound OP(=O)(O)CC(C)OC1=CC=C2OC(C=CCCCCCCC)(C)CCC2=C1 XOTFLRFOBUSVDA-UHFFFAOYSA-N 0.000 description 1
- RDNRUNGOBIBUMF-UHFFFAOYSA-N 2-[(2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]pentylphosphonic acid Chemical compound CCCC(CP(O)(O)=O)OC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 RDNRUNGOBIBUMF-UHFFFAOYSA-N 0.000 description 1
- UQEMXAJYDLZNRL-UHFFFAOYSA-N 2-[(2-methyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]propylphosphonic acid Chemical compound OP(=O)(O)CC(C)OC1=CC=C2OC(CCCCCCCCC)(C)CCC2=C1 UQEMXAJYDLZNRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KBFIAVMHQRHVTH-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnon-1-enyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]butylphosphonic acid Chemical compound O1C(C)(C=CCC(C)CCCC(C)C)CCC2=C(C)C(OC(CP(O)(O)=O)CC)=C(C)C(C)=C21 KBFIAVMHQRHVTH-UHFFFAOYSA-N 0.000 description 1
- XATZZEUFRZILQD-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnon-1-enyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]ethylphosphonic acid Chemical compound OP(=O)(O)CCOC1=C(C)C(C)=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1C XATZZEUFRZILQD-UHFFFAOYSA-N 0.000 description 1
- VRCPPDLTHOIFSZ-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnon-1-enyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]pentanoic acid Chemical compound O1C(C)(C=CCC(C)CCCC(C)C)CCC2=C(C)C(OC(CCC)C(O)=O)=C(C)C(C)=C21 VRCPPDLTHOIFSZ-UHFFFAOYSA-N 0.000 description 1
- YVBCOBUQLWEQPN-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnon-1-enyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]propylphosphonic acid Chemical compound OP(=O)(O)CC(C)OC1=C(C)C(C)=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1C YVBCOBUQLWEQPN-UHFFFAOYSA-N 0.000 description 1
- MVMQCNUGMUJZIK-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]ethanesulfonic acid Chemical compound OS(=O)(=O)CCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 MVMQCNUGMUJZIK-UHFFFAOYSA-N 0.000 description 1
- OKNRNTDIXOIOMF-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]ethylphosphonic acid Chemical compound OP(=O)(O)CCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 OKNRNTDIXOIOMF-UHFFFAOYSA-N 0.000 description 1
- BLQQGBFYXXLNBL-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]acetic acid Chemical compound OC(=O)COC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1C BLQQGBFYXXLNBL-UHFFFAOYSA-N 0.000 description 1
- IBAWSYRFOYPGNO-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]butane-1-sulfonic acid Chemical compound O1C(C)(CCCC(C)CCCC(C)C)CCC2=C(C)C(OC(CS(O)(=O)=O)CC)=C(C)C(C)=C21 IBAWSYRFOYPGNO-UHFFFAOYSA-N 0.000 description 1
- ZECKYPRJYVGHRD-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound O1C(C)(CCCC(C)CCCC(C)C)CCC2=C(C)C(OC(CC)C(O)=O)=C(C)C(C)=C21 ZECKYPRJYVGHRD-UHFFFAOYSA-N 0.000 description 1
- VZNCZFMRXFERRT-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]butylphosphonic acid Chemical compound O1C(C)(CCCC(C)CCCC(C)C)CCC2=C(C)C(OC(CP(O)(O)=O)CC)=C(C)C(C)=C21 VZNCZFMRXFERRT-UHFFFAOYSA-N 0.000 description 1
- FOHSUIJTZINGPV-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]ethanesulfonic acid Chemical compound OS(=O)(=O)CCOC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1C FOHSUIJTZINGPV-UHFFFAOYSA-N 0.000 description 1
- OQIGYUSGWYGSFW-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]ethylphosphonic acid Chemical compound OP(=O)(O)CCOC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1C OQIGYUSGWYGSFW-UHFFFAOYSA-N 0.000 description 1
- JAJGEDHKAHDSDB-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]hexanoic acid Chemical compound O1C(C)(CCCC(C)CCCC(C)C)CCC2=C(C)C(OC(CCCC)C(O)=O)=C(C)C(C)=C21 JAJGEDHKAHDSDB-UHFFFAOYSA-N 0.000 description 1
- YJFJEJQNAHWONM-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]pentane-1-sulfonic acid Chemical compound O1C(C)(CCCC(C)CCCC(C)C)CCC2=C(C)C(OC(CS(O)(=O)=O)CCC)=C(C)C(C)=C21 YJFJEJQNAHWONM-UHFFFAOYSA-N 0.000 description 1
- AJCHDKOVZRPIPL-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]pentanoic acid Chemical compound O1C(C)(CCCC(C)CCCC(C)C)CCC2=C(C)C(OC(CCC)C(O)=O)=C(C)C(C)=C21 AJCHDKOVZRPIPL-UHFFFAOYSA-N 0.000 description 1
- RDNWSMIXOVWYRU-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]pentylphosphonic acid Chemical compound O1C(C)(CCCC(C)CCCC(C)C)CCC2=C(C)C(OC(CP(O)(O)=O)CCC)=C(C)C(C)=C21 RDNWSMIXOVWYRU-UHFFFAOYSA-N 0.000 description 1
- GFBSKNPXEDNHBQ-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]propane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(C)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1C GFBSKNPXEDNHBQ-UHFFFAOYSA-N 0.000 description 1
- DAQARBHYNWIVOC-UHFFFAOYSA-N 2-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]ethanesulfonic acid Chemical compound OS(=O)(=O)CCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 DAQARBHYNWIVOC-UHFFFAOYSA-N 0.000 description 1
- VRBULPFUTRHTJX-UHFFFAOYSA-N 3-[(2,5,7,8-tetramethyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC1=C(C)C(C)=C2OC(C=CCCCCCCC)(C)CCC2=C1C VRBULPFUTRHTJX-UHFFFAOYSA-N 0.000 description 1
- YDIXGQJRPISVHF-UHFFFAOYSA-N 3-[(2,5,7,8-tetramethyl-2-non-1-enyl-3,4-dihydrochromen-6-yl)oxy]propanoic acid Chemical compound OC(=O)CCOC1=C(C)C(C)=C2OC(C=CCCCCCCC)(C)CCC2=C1C YDIXGQJRPISVHF-UHFFFAOYSA-N 0.000 description 1
- WMYTWSATLNWDMG-UHFFFAOYSA-N 3-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C WMYTWSATLNWDMG-UHFFFAOYSA-N 0.000 description 1
- QZZVXSKTRYAKLJ-UHFFFAOYSA-N 3-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]propanoic acid Chemical compound OC(=O)CCOC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C QZZVXSKTRYAKLJ-UHFFFAOYSA-N 0.000 description 1
- ULEBDYWDMHDNAQ-UHFFFAOYSA-N 3-[[2-(4,8-dimethylnon-1-enyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]propanoic acid Chemical compound OC(=O)CCOC1=C(C)C(C)=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1C ULEBDYWDMHDNAQ-UHFFFAOYSA-N 0.000 description 1
- JHIPMLWBPVEHTJ-UHFFFAOYSA-N 3-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 JHIPMLWBPVEHTJ-UHFFFAOYSA-N 0.000 description 1
- BFLSCLGFZZKDGU-UHFFFAOYSA-N 3-[[2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]propanoic acid Chemical compound OC(=O)CCOC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1C BFLSCLGFZZKDGU-UHFFFAOYSA-N 0.000 description 1
- IIFBMFHMUHAMKN-UHFFFAOYSA-N 3-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 IIFBMFHMUHAMKN-UHFFFAOYSA-N 0.000 description 1
- CCXRLUMFZDUEOS-UHFFFAOYSA-N 3-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]propylphosphonic acid Chemical compound OP(=O)(O)CCCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 CCXRLUMFZDUEOS-UHFFFAOYSA-N 0.000 description 1
- AMXPTINCMDTMKE-UHFFFAOYSA-N 4-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C AMXPTINCMDTMKE-UHFFFAOYSA-N 0.000 description 1
- OZEUUGNATVGTEM-UHFFFAOYSA-N 4-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]butanoic acid Chemical compound OC(=O)CCCOC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C OZEUUGNATVGTEM-UHFFFAOYSA-N 0.000 description 1
- NSBMWIXQXQRBEF-UHFFFAOYSA-N 4-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]butylphosphonic acid Chemical compound OP(=O)(O)CCCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 NSBMWIXQXQRBEF-UHFFFAOYSA-N 0.000 description 1
- OPTBXOXBCJWLGI-UHFFFAOYSA-N 4-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 OPTBXOXBCJWLGI-UHFFFAOYSA-N 0.000 description 1
- DHEJJDYXEFFCGA-UHFFFAOYSA-N 4-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]butylphosphonic acid Chemical compound OP(=O)(O)CCCCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 DHEJJDYXEFFCGA-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- GVGDYVFAZOHQDY-UHFFFAOYSA-N 5-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]pentane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 GVGDYVFAZOHQDY-UHFFFAOYSA-N 0.000 description 1
- REJZBLBJSNEEGK-UHFFFAOYSA-N 5-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]pentylphosphonic acid Chemical compound OP(=O)(O)CCCCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 REJZBLBJSNEEGK-UHFFFAOYSA-N 0.000 description 1
- NLAILVOWPBLRHK-UHFFFAOYSA-N 5-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]pentane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 NLAILVOWPBLRHK-UHFFFAOYSA-N 0.000 description 1
- IUTNDJDDMIJIED-UHFFFAOYSA-N 5-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]pentylphosphonic acid Chemical compound OP(=O)(O)CCCCCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 IUTNDJDDMIJIED-UHFFFAOYSA-N 0.000 description 1
- SIGORSQMCFETIU-UHFFFAOYSA-N 6-[(2,5,7,8-tetramethyl-2-nonyl-3,4-dihydrochromen-6-yl)oxy]hexane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCCCOC1=C(C)C(C)=C2OC(CCCCCCCCC)(C)CCC2=C1C SIGORSQMCFETIU-UHFFFAOYSA-N 0.000 description 1
- VYSSEIIMIVBXIE-UHFFFAOYSA-N 6-[[2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]hexylphosphonic acid Chemical compound OP(=O)(O)CCCCCCOC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 VYSSEIIMIVBXIE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PVPKIMVTVKQXIB-UHFFFAOYSA-N 8-[[2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxy]octanoic acid Chemical compound OC(=O)CCCCCCCOC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 PVPKIMVTVKQXIB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101001134300 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Multidomain regulatory protein Rv1364c Proteins 0.000 description 1
- 101000615835 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Phosphoserine phosphatase SerB2 Proteins 0.000 description 1
- 101001082202 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Triple specificity protein phosphatase PtpB Proteins 0.000 description 1
- 101001134301 Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh) Multidomain regulatory protein MT1410 Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000242743 Renilla reniformis Species 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- OACYWALECUSMHH-UHFFFAOYSA-N [2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxymethanesulfonic acid Chemical compound OS(=O)(=O)COC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 OACYWALECUSMHH-UHFFFAOYSA-N 0.000 description 1
- OZPAYCMCMAARAQ-UHFFFAOYSA-N [2-(4,8-dimethylnon-1-enyl)-2-methyl-3,4-dihydrochromen-6-yl]oxymethylphosphonic acid Chemical compound OP(=O)(O)COC1=CC=C2OC(C=CCC(C)CCCC(C)C)(C)CCC2=C1 OZPAYCMCMAARAQ-UHFFFAOYSA-N 0.000 description 1
- XMRXQZDJLXLWAB-UHFFFAOYSA-N [2-(4,8-dimethylnonyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxymethylphosphonic acid Chemical compound OP(=O)(O)COC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1C XMRXQZDJLXLWAB-UHFFFAOYSA-N 0.000 description 1
- OWKGFJMHUVIVAT-UHFFFAOYSA-N [2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxymethanesulfonic acid Chemical compound OS(=O)(=O)COC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 OWKGFJMHUVIVAT-UHFFFAOYSA-N 0.000 description 1
- MURDSDTUCMZHJD-UHFFFAOYSA-N [2-(4,8-dimethylnonyl)-2-methyl-3,4-dihydrochromen-6-yl]oxymethylphosphonic acid Chemical compound OP(=O)(O)COC1=CC=C2OC(CCCC(C)CCCC(C)C)(C)CCC2=C1 MURDSDTUCMZHJD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- FGJLAJMGHXGFDE-UHFFFAOYSA-L disodium;2,3-dihydroxybutanedioate;dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C(O)C(O)C([O-])=O FGJLAJMGHXGFDE-UHFFFAOYSA-L 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- RJQRCOMHVBLQIH-UHFFFAOYSA-M pentane-1-sulfonate Chemical compound CCCCCS([O-])(=O)=O RJQRCOMHVBLQIH-UHFFFAOYSA-M 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229940092162 sodium tartrate dihydrate Drugs 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16875909P | 2009-04-13 | 2009-04-13 | |
| US61/168,759 | 2009-04-13 | ||
| PCT/US2010/030799 WO2010120711A1 (en) | 2009-04-13 | 2010-04-13 | Protein phosphatase 2a-activating agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012523458A true JP2012523458A (ja) | 2012-10-04 |
| JP2012523458A5 JP2012523458A5 (enExample) | 2013-03-28 |
Family
ID=42981438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506102A Pending JP2012523458A (ja) | 2009-04-13 | 2010-04-13 | タンパク質ホスファターゼ２ａ活性化剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8461362B2 (enExample) |
| EP (1) | EP2419414A4 (enExample) |
| JP (1) | JP2012523458A (enExample) |
| AU (1) | AU2010236655A1 (enExample) |
| CA (1) | CA2758823A1 (enExample) |
| WO (1) | WO2010120711A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012524070A (ja) * | 2009-04-17 | 2012-10-11 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | 抗接着剤 |
| JP2018508752A (ja) * | 2014-12-31 | 2018-03-29 | フリューダイム カナダ インコーポレイテッド | マスサイトメトリーによる分析用の構造化生体試料 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007143081A2 (en) * | 2006-06-02 | 2007-12-13 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
| JP2012523458A (ja) | 2009-04-13 | 2012-10-04 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | タンパク質ホスファターゼ２ａ活性化剤 |
| US8309768B2 (en) | 2010-11-29 | 2012-11-13 | The Ohio State University Research Foundation | FTY720-derived anticancer agents |
| US9220706B2 (en) | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
| JP2018518522A (ja) * | 2015-06-23 | 2018-07-12 | ケース ウエスタン リザーブ ユニバーシティ | 癌を治療するための組成物及び方法 |
| KR20180035905A (ko) | 2015-08-10 | 2018-04-06 | 다나-파버 캔서 인스티튜트 인크. | Bet 브로모도메인 억제제에 대한 저항성의 메카니즘 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002121132A (ja) * | 2000-08-09 | 2002-04-23 | Showa Denko Kk | 発がん抑制剤および発がん抑制方法 |
| JP2004504268A (ja) * | 2000-02-11 | 2004-02-12 | リサーチ ディベロップメント ファンデーション | トコフェロール、トコトリエノール、その他のクロマン、及びそれらの側鎖誘導体とその利用法 |
| JP2009538823A (ja) * | 2006-02-21 | 2009-11-12 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | 抗癌剤 |
| JP2012524070A (ja) * | 2009-04-17 | 2012-10-11 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | 抗接着剤 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2680749A (en) * | 1951-12-01 | 1954-06-08 | Eastman Kodak Co | Water-soluble tocopherol derivatives |
| DE2822324C3 (de) * | 1978-05-22 | 1981-02-26 | Basf Ag, 6700 Ludwigshafen | Herstellung von Vitamin-E-Trockenpulver |
| JPS59222415A (ja) | 1983-05-31 | 1984-12-14 | Kuraray Co Ltd | 免疫調節剤 |
| US4751224A (en) * | 1983-07-21 | 1988-06-14 | Brown University Research Foundation | Treatment of metastasis |
| ATE279185T1 (de) * | 1995-12-28 | 2004-10-15 | Mitsubishi Pharma Corp | 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden |
| US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| US6770672B1 (en) * | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6703384B2 (en) * | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| RU2232758C2 (ru) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием |
| WO2003011280A1 (en) * | 2001-07-27 | 2003-02-13 | University Of Rochester | Use of vitamin e succinate and antiandrogen combination |
| US6858227B1 (en) * | 2001-11-21 | 2005-02-22 | Sonus Pharmaceuticals, Inc. | Vitamin E conjugates |
| US20050215531A1 (en) * | 2002-05-16 | 2005-09-29 | Thomas Baumruker | Use of edg receptor binding agents in cancer |
| US20050090520A1 (en) * | 2003-09-12 | 2005-04-28 | Per Lindquist | Treatment of disease or injury of the nervous system with FTY720 |
| CA2580584C (en) * | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
| PT1961734E (pt) * | 2005-12-15 | 2011-10-06 | Mitsubishi Tanabe Pharma Corp | Composto de amina e sua utilização para fins médicos |
| WO2007143081A2 (en) | 2006-06-02 | 2007-12-13 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of lymphoid malignancies |
| WO2008021532A2 (en) | 2006-08-17 | 2008-02-21 | University Of Chicago | Treatment of inflammatory diseases |
| JP5396274B2 (ja) * | 2006-09-15 | 2014-01-22 | スティーブン・ジョン・ラルフ | プロオキシダント抗ガン化合物 |
| JP4481316B2 (ja) * | 2007-01-09 | 2010-06-16 | 株式会社エヌ・ティ・ティ・ドコモ | ユーザ装置および送信方法 |
| WO2008153159A1 (ja) * | 2007-06-14 | 2008-12-18 | Mitsubishi Tanabe Pharma Corporation | アミン化合物及びその医薬用途 |
| AU2009304596A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| JP2012523458A (ja) | 2009-04-13 | 2012-10-04 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | タンパク質ホスファターゼ２ａ活性化剤 |
-
2010
- 2010-04-13 JP JP2012506102A patent/JP2012523458A/ja active Pending
- 2010-04-13 US US12/758,858 patent/US8461362B2/en not_active Expired - Fee Related
- 2010-04-13 AU AU2010236655A patent/AU2010236655A1/en not_active Abandoned
- 2010-04-13 CA CA2758823A patent/CA2758823A1/en not_active Abandoned
- 2010-04-13 EP EP10764981.6A patent/EP2419414A4/en not_active Withdrawn
- 2010-04-13 WO PCT/US2010/030799 patent/WO2010120711A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004504268A (ja) * | 2000-02-11 | 2004-02-12 | リサーチ ディベロップメント ファンデーション | トコフェロール、トコトリエノール、その他のクロマン、及びそれらの側鎖誘導体とその利用法 |
| JP2002121132A (ja) * | 2000-08-09 | 2002-04-23 | Showa Denko Kk | 発がん抑制剤および発がん抑制方法 |
| JP2009538823A (ja) * | 2006-02-21 | 2009-11-12 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | 抗癌剤 |
| JP2012524070A (ja) * | 2009-04-17 | 2012-10-11 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | 抗接着剤 |
Non-Patent Citations (4)
| Title |
|---|
| JPN6014025157; Ｃｈｕｎｇ-Ｗａｉ Ｓｈｉａｕ， Ｊｕｉ-Ｗｅｎ Ｈｕａｎｇ， Ｄａ-Ｓｈｅｎｇ Ｗａｎｇ， Ｊｉｎｇ-Ｒｕ Ｗｅｎｇ， Ｃｈｉｈ-Ｃｈｅｎｇ Ｙａｎｇ， Ｃｈｉａ-Ｈｕｉ Ｌｉｎ， Ｃｈｅｎｇｌｏｎ: 'alpha-Ｔｏｃｏｐｈｅｒｙｌ Ｓｕｃｃｉｎａｔｅ Ｉｎｄｕｃｅｓ Ａｐｏｐｔｏｓｉｓ ｉｎ Ｐｒｏｓｔａｔｅ Ｃａｎｃｅｒ Ｃｅｌｌｓ ｉｎ Ｐａｒｔ ｔｈｒｏｕｇｈ Ｉｎｈｉｂｉｔｉｏｎ ｏｆ Ｂｃｌ' Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ ｖｏｌ．２８１， Ｎｏ．１７, 20060428, ｐ&#x * |
| JPN6014025158; Ｐａｕｌ Ｌ． Ｃｒｉｓｐｅｎ， Ｒｏｂｅｒｔ Ｇ． Ｕｚｚｏ， Ｋｏｎｓｔａｎｔｉｎ Ｇｏｌｏｖｉｎｅ， Ｐｅｔｅｒ Ｍａｋｈｏｖ， Ａｌａｎ Ｐｏｌｌａｃｋ， Ｅｒｉｃ Ｍ． Ｈｏｒｗｉｔｚ， Ｒ: 'Ｖｉｔａｍｉｎ Ｅ Ｓｕｃｃｉｎａｔｅ Ｉｎｈｉｂｉｔｓ ＮＦ-ｋＢ ａｎｄ Ｐｒｅｖｅｎｔｓ ｔｈｅ Ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ａ Ｍｅｔａｓｔａｔｉｃ Ｐｈｅｎｏｔｙｐｅ ｉｎ Ｐｒｏｓｔａｔ' Ｔｈｅ Ｐｒｏｓｔａｔｅ ｖｏｌ．６７， Ｎｏ．６, 20070501, ｐ．５８２-５９０, Ｊｏｈｎ Ｗｉｌｅｙ ＆ Ｓｏ&#x * |
| JPN6014025159; Ｊｉｒｉ Ｎｅｕｚｉｌ， Ｔｏｂｉａｓ Ｗｅｂｅｒ， Ａｎｄｒｅａｓ Ｓｃｈｒｏｄｅｒ， Ｍｉｎ Ｌｕ， Ｇｅｏｒｇ Ｏｓｔｅｒｍａｎｎ， Ｎｉｎａ Ｇｅｌｌｅｒｔ， Ｇｅｏｒｇｅ Ｃ． Ｍａｙｎｅ，: 'Ｉｎｄｕｃｔｉｏｎ ｏｆ ｃａｎｃｅｒ ｃｅｌｌ ａｐｏｐｔｏｓｉｓ ｂｙ alpha-ｔｏｃｏｐｈｅｒｙｌ ｓｕｃｃｉｎａｔｅ： ｍｏｌｅｃｕｌａｒ ｐａｔｈｗａｙｓ ａｎｄ ｓｔｒｕｃｔｕｒａｌ ｒｅｑ' Ｔｈｅ ＦＡＳＥＢ Ｊｏｕｒｎａｌ ｖｏｌ．１５， Ｎｏ．２, 20010201, ｐ．４０３-４１５, Ｔｈｅ Ｆｅｄｅｒａｔ * |
| JPN6014025160; Ｐｏ-Ｈｓｉｅｎ Ｈｕａｎｇ， Ｄａｓｈｅｎｇ Ｗａｎｇ， Ｈｓｉａｏ-Ｃｈｉｎｇ Ｃｈｕａｎｇ， Ｓｈｕｏ Ｗｅｉ， Ｓａｍｕｅｌ Ｋ．Ｋｕｌｐ， Ｃｈｉｎｇ-Ｓｈｉｈ Ｃｈｅｎ: 'alpha-Ｔｏｃｏｐｈｅｒｙｌ Ｓｕｃｃｉｎａｔｅ ａｎｄ ｄｅｒｉｖａｔｉｖｅｓ ｍｅｄｉａｔｅ ｔｈｅ ｔｒａｎｓｃｒｉｐｔｉｏｎａｌ ｒｅｐｒｅｓｓｉｏｎ ｏｆ ａｎｄｒｏｇｅｎ ｒｅｃｅｐｔｏｒ' Ｃａｒｃｉｎｏｇｅｎｅｓｉｓ ｖｏｌ．３０， Ｎｏ．７, 200907, ｐ．１１２５-１１３１, Ｏｘｆｏｒｄ Ｕｎｉｖｅｒｓｉｔｙ Ｐｒｅｓｓ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012524070A (ja) * | 2009-04-17 | 2012-10-11 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | 抗接着剤 |
| JP2018508752A (ja) * | 2014-12-31 | 2018-03-29 | フリューダイム カナダ インコーポレイテッド | マスサイトメトリーによる分析用の構造化生体試料 |
| US10847357B2 (en) | 2014-12-31 | 2020-11-24 | Fluidigm Canada Inc. | Structured biological samples for analysis by mass cytometry |
Also Published As
| Publication number | Publication date |
|---|---|
| US8461362B2 (en) | 2013-06-11 |
| AU2010236655A1 (en) | 2011-11-17 |
| WO2010120711A1 (en) | 2010-10-21 |
| EP2419414A1 (en) | 2012-02-22 |
| CA2758823A1 (en) | 2010-10-21 |
| EP2419414A4 (en) | 2013-12-04 |
| US20100267673A1 (en) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8461362B2 (en) | Protein phosphatase 2A-activating agents | |
| Yang et al. | Activity-based proteome profiling of potential cellular targets of orlistat− an FDA-approved drug with anti-tumor activities | |
| Nambiar et al. | Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1 | |
| Yao et al. | Sulforaphane inhibited expression of hypoxia‐inducible factor‐1α in human tongue squamous cancer cells and prostate cancer cells | |
| CN108309982B (zh) | 3位取代的5H-[1,2,4]三嗪[5,6-b]吲哚衍生物的用途 | |
| Monteiro et al. | DUSP3/VHR: a druggable dual phosphatase for human diseases | |
| Reel et al. | The regulation of matrix metalloproteinase expression and the role of discoidin domain receptor 1/2 signalling in zoledronate-treated PC3 cells | |
| Wang et al. | Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives | |
| Shearn et al. | Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibition by 4-hydroxynonenal leads to increased Akt activation in hepatocytes | |
| CN112055586A (zh) | 苯磺酰胺衍生物及调节脂膜筏的方法 | |
| KR101482803B1 (ko) | 산화 촉진제 항암 화합물 | |
| US20030236294A1 (en) | Compounds and methods for inducing apoptosis in proliferating cells | |
| EP2418948B1 (en) | Antiadhesion agents | |
| Yang et al. | Isowalsuranolide targets TrxR1/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB/TFE3 axis | |
| US8383656B2 (en) | Thiazolidinedione energy restriction-mimetic agents | |
| Huang et al. | Side chain-functionalized aniline-derived ursolic acid derivatives as multidrug resistance reversers that block the nuclear factor-kappa B (NF-κB) pathway and cell proliferation | |
| EP2909171B1 (fr) | Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer | |
| KR101207981B1 (ko) | 호르몬 불응성 전립선암의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법 | |
| US20160287562A1 (en) | Method for the treatment of nf1- or ras-associated disorders | |
| Mangalpady et al. | Synthesis and Evaluation of α-Amylase and Lipase Inhibitory Activities of Synthetic Coumarin Derivatives | |
| Viehoever et al. | Therapeutic interference of SREBP-mediated lipid metabolism by E-Xanthohumol attenuates prostate cancer progression | |
| Estévez Braun et al. | 1, 2, 3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors | |
| Huang | Novel small molecules regulating the histone marking, AR signaling, and Akt inhibition in prostate cancer | |
| Ziegler | Effects of resveratrol on tumor load, tumor COX-2 expression and tumor PGE2 biosynthesis in a murine model of intestinal tumorigenesis | |
| Vélez Bernal et al. | Synthesis and antiprotozoal activity of furanchalcone-quinoline, furanchalcone-chromone and furanchalcone-imidazole hybrids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140618 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150126 |